Loss of SETD2 was shown to sensitize ccRCC cells to the PI3K (Phospoinositide 3-kinase) inhibitors TGX221 and AZD6482, thus decreasing the invasive potential of the targeted population [62]. Here, SETD2 is linked to nonpapillary renal cell carcinoma.